Alkermes Management to Discuss Strategy at Goldman Sachs Healthcare Conference
Event summary
- Alkermes management to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
- Live webcast available on Alkermes' website, archived for 14 days.
- Alkermes focuses on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy.
- Pipeline includes late-stage candidates for narcolepsy and idiopathic hypersomnia, and early-stage orexin 2 receptor agonists for ADHD, multiple sclerosis, and Parkinson’s disease.
The big picture
Alkermes' participation in the Goldman Sachs Healthcare Conference underscores its focus on strategic communication amid a competitive biopharmaceutical landscape. The company's pipeline and commercial products position it within the neuroscience sector, where innovation and execution are critical for market differentiation. The event provides a platform for Alkermes to articulate its vision and address investor concerns about its growth trajectory.
What we're watching
- Pipeline Progress
- How the advancement of late-stage and early-stage candidates will impact Alkermes' market position.
- Market Positioning
- Whether Alkermes can sustain growth in the competitive neuroscience market.
- Investor Sentiment
- The pace at which investor interest and confidence in Alkermes' strategy evolves post-conference.